- Oikotie Työpaikat
- Jätä ilmoitus
Orion’s pharmaceutical innovations are created within its R&D organization, including non-clinical research and clinical development. The organization employs top professionals in the field of drug development. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs.
We have seen growth in R&D productivity over the last years and have now an exciting R&D pipeline. In order to ensure future development, we have started to build capabilities for biologics discovery. In addition we are strengthening our power in small molecule research. Experienced professionals with new competencies are needed to guarantee our continuous success.
The recently established Biologics function is part of our R&D organization and it is responsible for bringing forward our biologics pipeline. To fulfill this exciting task, the Biologics function is now recruiting several R&D experts with a track record of developing therapeutic antibodies. The function is new and you have a great opportunity to be part of developing its processes.
We are looking for two Cell Biologists for Antibody Discovery who provide scientific and technological expertise for biologics and therapeutic antibody development in the laboratory.
The first role will focus on characterizing the molecular and cellular action of antibodies using advanced cell engineering and cell biological techniques.
The second role will focus on characterization of new therapeutic antibodies in laboratory and the work will include immunological assay setups and validation, as well as binding and functional studies, for example studying effector functions.
In both roles you will also be involved in choosing the optimal technology for antibody generation. Both Cell Biologists will spend time in the laboratory doing hands-on research, however part of the work is also done in cooperation with CROs (contract research organization).
For both roles we expect you to have a relevant PhD for example in Cell Biology, Molecular Biology or Biochemistry, with a strong track record of developing therapeutic antibodies. We value work experience in the pharmaceutical industry or a long academic career. We hope that you have contributed significantly in Microscopy (Immunofluorescence and/or High Content Imaging) and/or Flow cytometry experiments. We also hope that you have experience in working with partners.
In addition, for the first role we expect you to have thorough hands-on laboratory experience regarding molecular and cellular mechanisms of therapeutic antibodies. For the second role we expect you to have thorough hands-on experience of laboratory work related to antibody generation as well as mode of action studies.
We are looking for high influencers in their area of expertise. Taking independent responsibility even in new situations will lead to success in these positions. These jobs also require superb networking and negotiation skills. We also value high problem-solving skills, in-depth analytical thinking and a touch of creativity. Our main working language is English therefore we expect excellent English language skills.
We offer exciting opportunities to create and have an impact on future therapies for patients.
We also offer you attractive career development opportunities to use your own strengths for development. The culture of Orion R&D is informal and we enjoy working together.
Join us – together we build well-being and do work that we are proud of!
The positions are located in Turku, Finland. If you are located somewhere else in the world at the moment you might want to check the areas Finland is considered a leader in the world http://www.huffingtonpost.com/ira-kalb/finland-is-still-the-worl_b_10774930.html
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion’s net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion’s A and B shares are listed on NASDAQ Helsinki.